New pain drug hits target, misses CNS

The fast-growing drug discovery arm of the Italian Institute of Technology has published a preclinical study in which a novel pain therapy with front-line potential was able to deliver a shot of pain relief in tissue while detouring the central nervous system. The Drug Discovery and Development unit, dubbed D3, said that URB937 works in peripheral tissue by inhibiting the enzyme fatty acid amide hydrolase (FAAH). The drug controls pain and inflammation at the specific site it originates in by boosting levels of anandamide. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.